Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast reconstruction cases in Minnesota: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 17% on average (125 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 344 | 49% |
| 2020 | 0 | 237 | 52% |
| 2021 | 0 | 212 | 56% |
| 2022 | 0 | 202 | 59% |
| 2023 | 1 | 246 | 62% |
| 2024 | 1 | 226 | 64% |
| 2025 from claims | – | 246 199–289 | 65% |
| 2026 forecast | – | 276 216–347 | 61% |
| 2027 forecast | – | 283 210–375 | 61% |
| 2028 forecast | – | 290 206–401 | 61% |
| 2029 forecast | – | 298 202–427 | 60% |
| 2030 forecast | – | 305 200–453 | 60% |
Implant- and flap-based reconstruction; ADM and expander call point. Professional codes (what the surgeon bills): CPT 19357, 19340, 19342, 19364, 19380.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Minnesota; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 84% hospital outpatient, 16% surgery center.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 3 | 597−7.9%/yr | −7.9%/yr | 0.4 | 0% | 1,560 in 2030+17%/yr |
| Ohio | 1 | 469−2.5%/yr | −2.5%/yr | 0.4 | 0% | 380 in 2030−3.5%/yr |
| Michigan | 1 | 303−11%/yr | −11%/yr | 0.4 | 0% | 190 in 2030−7.5%/yr |
| Missouri | 1 | 273−7.1%/yr | −7.1%/yr | 0.4 | 0% | 200 in 2030−4.9%/yr |
| Indiana | 0 | 272−5%/yr | −5%/yr | 0.4 | 23% | 190 in 2030−6.1%/yr |
| Kansas | 0 | 213−7.1%/yr | −7.1%/yr | 0.5 | 39% | 160 in 2030−4.9%/yr |
| Wisconsin | 0 | 200−7%/yr | −7%/yr | 0.4 | 0% | 210 in 2030+1%/yr |
| Iowa | 0 | 141−3.2%/yr | −3.2%/yr | 0.3 | 0% | 120 in 2030−3%/yr |
| South Dakota | 0 | 114−2.1%/yr | −2.1%/yr | 0.9 | 0% | 130 in 2030+1.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 18 | 2,581−3.2%/yr | −3.2%/yr | 6.11.0× | 8% | 3,830 in 2030+6.8%/yr |
| Cholecystectomy & appendectomy | 23 | 1,976−5.3%/yr | −5.3%/yr | 4.51.0× | 2% | 2,420 in 2030+3.5%/yr |
| Colorectal resection | 1 | 849−4.5%/yr | −4.5%/yr | 1.91.1× | 0% | 1,120 in 2030+4.8%/yr |
| Antireflux & hiatal hernia surgery | 3 | 341−4.9%/yr | −4.9%/yr | 0.81.0× | 0% | 500 in 2030+6.7%/yr |
Breast reconstruction in every state, and its device makers · Every procedure market in Minnesota · Every state · Compare with Illinois
Abbvie leads with 68% of company spending on these surgeons in 2025, −18 pts on 2024.
In 2025, 9 companies reported engagement with Minnesota’s surgeons worth $22K in consulting, speaking, meals and travel tied to these products, about $22K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.